Dataset Information

Characterization of the menin-MLL interaction as therapeutic cancer target in solid tumor models

ABSTRACT: Background: Inhibition of the interaction of the scaffold protein menin with the histone methyltransferase MLL1 (KMT2A) has recently emerged as a novel therapeutic strategy in different cancers. Purpose: Here we validate the proposed pathogenic function of the menin-MLL interaction in cancer with a novel probe inhibitor BAY-155. Methods: RNA-seq was used to investigate transcriptional effects of novel BAY-155 probe in thirteen cell lines from a range of solid tumor types. Results: Menin-MLL inhibition by BAY-155 in colorectal (SW1463, LoVo, DLD-1), prostate (22RV1, LNCaP, VCaP), pancreas (PANC-1, MiaPaCa2), breast (BT-474, ZR-75-1, MCF7), bladder (JMSU-1) and kidney (G401) tissue derived cancer cell lines resulted in moderate gene expression changes. Surprisingly, for the reported role of MLL1 as a co-activator of gene expression, inhibition by BAY-155 led predominantly to up-regulation of genes. We could not observe any evidences of an overarching, menin driven expression program, which is in contrast to previous reports for e.g. the Hox gene cluster. Conclusions: Our study adds important critical validation data to the menin-MLL interaction as therapeutic target in solid cancers. By using a more selective and potent inhibitor we propose that the potential therapeutic benefit of disrupting the menin-MLL interaction may be more restricted to specific cancers than previously predicted.

ORGANISM(S): Homo sapiens

PROVIDER: GSE136272 | GEO | 2020/02/27

REPOSITORIES: GEO

ACCESS DATA

Similar Datasets

Project description:Purpose: The chromosomal rearrangements of the mixed-lineage leukemia (MLL) gene have been extensively characterized as a potent oncogenic driver on the molecular and mechanistic level in acute lymphoblastic (ALL) and acute myeloid (AML) leukemia. For its oncogenic function the MLL fusion protein is hijacking the the multi enzyme super elongation complex (SEC) leading to elevated expression of MLL target genes (e.g. HOXA9 and MEIS). High expression of MLL target genes is overwriting the normal hematopoietic differentiation gene expression program, resulting in undifferentiated blasts cells having a more “stem-cell like” cancer-promoting phenotype. Although extensive resources have been devoted to a better understanding of therapeutic targets for the MLL fusion to overcome the de-differentiation, the inter-dependencies of those targets for the pathophysiology of MLL is still barely understood. Here we report a comparative mode of action analysis of different inhibitors potentially interfering with MLL fusion induced differentiation blockade. We used RNA-seq for transcriptomic profiling in 14 AML and ALL cell lines treated with DMSO control or one of the 5 studied inhibitors (EPZ-5676, Brequinar, BAY-155, BAY-1251152 and OTX015). Methods: We used RNA-seq for transcriptomic profiling in 14 AML and ALL cell lines treated with DMSO control or one of the 5 studied inhibitors (EPZ-5676, Brequinar, BAY-155, BAY-1251152 and OTX015). Results: We discovered significant differences between compounds in their ability to induce differentiation and interfere with MLL target genes expression. We observed that Menin and DOT1L inhibition act very specifically on MLL fused leukemia cell lines, whereas inhibition of BET, DHODH and P-TEFb have strong effects beyond the MLL fusion . Conclusions: These results show a substantial diversity in the molecular activities of those inhibitors and provide valuable insights into the further developmental potential as single agents or in combinations in MLL fused leukemias.

Dataset Information

Characterization of the menin-MLL interaction as therapeutic cancer target in solid tumor models

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure